Saturday

27th Feb 2021

Coronavirus

EU silent on US buying up world's remdesivir supplies

The European Commission on Wednesday (1 July) refused to speak out against the US decision to buy up most of the world's stock of remdesivir.

The drug, manufactured by the US-based biopharmaceutical company Gilead, has been proven to work against Covid-19.

Read and decide

Join EUobserver today

Become an expert on Europe

Get instant access to all articles — and 20 years of archives. 14-day free trial.

... or subscribe as a group

Two of the most senior European Commission officials, vice-presidents Margaritis Schinas and Valdis Dombrovskis, declined to respond to questions on the US move during a press conference on Wednesday.

Instead, the European Commission's official spokesperson services in an email sent later in the day announced it had taken "note of the announcement made yesterday regarding doses available for the US."

The tiptoeing may be due to broader efforts by the Commission to negotiate with Gilead for reserve doses of remdesivir for EU member states.

"Given the confidentiality of these discussions, no details can be given at this stage," said European commission spokesperson, Stefan de Keersmaecker, in an emailed statement.

But with the US buying up three months of stocks, leaving Europe and most the world without, the commission's strategy to secure the drug is likely to pose some tricky questions.

The Trump administration bought more than 500,000 doses, spanning all of Gilead's production for July and throughout most of autumn.

Similar tactics by the Trump administration in March to acquire the exclusive rights to a vaccine being developed by CureVac, a German firm, were roundly condemned.

In May, the French government expressed outrage after the CEO of the French pharmaceutical giant Sanofi said the US would get first doses on any Covid-19 vaccine.

Meanwhile, Germany on Wednesday told Reuters news agency it had secured sufficient supplies of remdesivir.

"The federal government has early on secured remdesivir for the treatment of coronavirus patients. Currently, there are still sufficient reserves," Germany's health ministry told Reuters in a written statement.

The Amsterdam-based European Medicines Agency (EMA) had only last week recommended granting a conditional marketing authorisation for remdesivir.

The drug is the first and so far the only Covid-19 treatment recommended for EU authorisation.

"As of 15 June, EMA has been in contact with developers of 132 potential Covid-19 therapeutics and 34 potential vaccines," the EMA said in an email.

For its part, the commission says their decision to speed up the process to grant a marketing authorisation for remdesivir in the coming days, is a demonstration of their commitment to ensure that scientifically proven effective treatments for Covid-19 are available to EU citizens.

Analysis

Waking up after corona. How will the world look?

Many people hoped that after corona we would wake up in a friendlier world. Unfortunately, the opposite seems to be the case. A cocktail of several fears is fuelling the already existing trend of polarisation, worldwide.

Investigation

EU taxpayers in the dark on US corona-drug deal

The EU recently signed a huge contract for a US anti-corona drug which, the WHO says, might not work, but there's little transparency on how the deal was made.

News in Brief

  1. EU leaders restate defence 'autonomy' plan
  2. Rights group exposes Ethiopia massacre
  3. US carried out airstrikes against Iran-backed militia in Syria
  4. Malta closes investigation into journalist murder
  5. Dutch parliament calls China treatment of Uighurs genocide
  6. Spain fined €15m by ECJ over data failures
  7. Belarus: Anti-government protester jailed for 10 years
  8. German charged with spying for Russia in Bundestag

Opinion

Together Europe can beat pandemics, Alzheimer's, cancer

Let's expand the EU with a Health Union where cutting edge research and world-class applications go hand in hand. For this, it is worth being European, believing in Europe, working on Europe, writes European People's Party leader Manfred Weber MEP.

Stakeholders' Highlights

  1. Nordic Council of MinistersNordic Council to host EU webinars on energy, digitalisation and antibiotic resistance
  2. UNESDAEU Code of Conduct can showcase PPPs delivering healthier more sustainable society
  3. CESIKlaus Heeger and Romain Wolff re-elected Secretary General and President of independent trade unions in Europe (CESI)
  4. Nordic Council of MinistersWomen benefit in the digitalised labour market
  5. Nordic Council of MinistersReport: The prevalence of men who use internet forums characterised by misogyny
  6. Nordic Council of MinistersJoin the Nordic climate debate on 17 November!

Latest News

  1. Armenia 'coup' shows waning of EU star in South Caucasus
  2. 'Difficult weeks' ahead, as variants spread across EU
  3. EU top court advised to strike down Hungary's asylum policy
  4. Frontex chief: 'about time' MEPs probe his agency
  5. Is EU poised to solve child labour in 'green' batteries?
  6. The trap of spreading ideas while attacking them
  7. Who are the EU's new Russian deplorables?
  8. Afghan asylum family beaten in Greece, set adrift at sea

Join EUobserver

Support quality EU news

Join us